News | Cath Lab | January 23, 2017

New Report Highlights National Trends in Heart Disease Treatments

Data show registries are advancing effectiveness and safety of patient care

NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care

January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to new data. The data are part of a broad report on trends in heart disease care from the American College of Cardiology’s National Cardiovascular Data Registry, published in the Journal of the American College of Cardiology.

The report “Trends in Cardiovascular Care in the United States: a Report from Four American College of Cardiology National Cardiovascular Data Registry Programs,” provides insights into the patient populations, participating centers and patterns of care based on 2014 data from four of the 10 NCDR programs — CathPCI Registry, ICD Registry, ACTION Registry-GWTG and IMPACT Registry. 

The authors of the report said the registry data provide unique perspectives into the care and outcomes of heart disease care in the United States and illustrate the strength of national quality programs, like NCDR, in advancing the effectiveness and safety of treatments for heart disease patients.

“We were able to report on the care and outcomes of patients undergoing common cardiovascular procedures, including percutaneous coronary interventions, implantable defibrillators and interventions for congenital heart disease, as well as for patients with acute heart attacks,” NCDR Management Board Chair and lead author of the study Frederick A. Masoudi, M.D., MSPH, FACC, said. “In some cases, hospitals are consistently providing excellent care; the registries, however, allow us to identify those aspects of care where the cardiovascular clinical community can improve.”

Key findings from each registry include:

CathPCI Registry

  • Of the 667,424 patients undergoing PCI in 2014, 35.3 percent of PCIs were performed for elective indications, compared to 64.7 percent performed for non-elective indications;
  • Between 2011 and 2014, the use of femoral access decline from 88.4 percent to 74.5 percent, while the use of radial access increased from 10.9 percent to 25.2 percent;
  • Use of evidence-based therapies, including aspirin, P2Y12 inhibitors and statins for eligible patients, continue to remain high at 93.3 percent;
  • Median door-to-balloon time for primary PCI for ST-elevation myocardial infarction (STEMI) also remains strong at 59 minutes for patients receiving PCI at the presenting hospital and 105 minutes for transfer patients.

ICD Registry

  • Of the 158,649 patients receiving implantable cardioverter defibrillator (ICD) therapy in 2014, 120,228 received a device for primary prevention reasons, compared to 38,421 who received a device for secondary prevention indications;
  • Of all ICD implants in 2014, 25 percent involved single chamber devices, 32 percent involved dual chamber devices and 43 percent involved cardiac resynchronization therapy-defibrillator (CRT-D) devices, compared to 19 percent, 37 percent and 44 percent, respectively, in 2011; and
  • While use of evidence-based therapies are generally high, performance on a composite medication metric, including use of ACE or ARB for patients with left ventricular systolic dysfunction (LVSD) and beta blockers for patients with LVSD, could be a target for quality improvement efforts. Between 2011 and 2014 the composite rate of use grew from 76.7 percent to 80.3 percent, with room for continued improvement.

ACTION Registry-GWTG

  • Of the 182,903 patients with acute myocardial infarction (AMI) in 2014, 71,368 had STEMI, while 111,535 had non-ST-segment elevation acute coronary syndromes (NSTEMI);
  • There is room for improvement in the areas of overall defect-free care (78.4 percent); P2Y12 inhibitor use in eligible patients (56.7 percent); and use of aldosterone antagonists in patients with LV systolic dysfunction and either diabetes or heart failure (12.8 percent);
  • Compared to NSTEMI patients, STEMI patients were more likely to experience certain adverse events during hospitalization, including death (6.4 percent vs. 3.4 percent); cardiogenic shock (4.4 percent vs. 1.6 percent), or bleeding (8.5 percent vs. 5.5 percent); and
  • Of the STEMI patients, 95.8 percent underwent coronary angiography and 90.7 percent underwent PCI, compared to NSTEMI patients of which 81.9 percent underwent coronary angiography and 52.4 percent underwent PCI.

IMPACT Registry

  • Of the 20,169 patients with congenital heart disease undergoing cardiac catheterization or a catheter-based intervention, 86 percent were under the age of 18 and 24.6 percent were under one year old;
  • Procedures such as atrial septal defect (ASD) closure, patent ductus arteriosus (PDA) closure, aortic coarctation stenting and pulmonary valvulolasty had success rates exceeding 84 percent. Aortic coarctation balloon angioplasty was less successful at 55.1 percent; and
  • Device embolization was reported in 1.2 percent of ASD closure procedures and 1.1 percent of PDA closure procedures. A clinically significant increase in aortic regurgitation follow valvuloplasty was noted in 10.6 percent of cases.

In a corresponding executive summary also published in JACC, Masoudi said, “NCDR data provide a unique, clinically rich national perspective on the care and outcomes of high-impact cardiovascular conditions and procedures that are not available elsewhere.”

The full report can be read here.

For more information: www.jacc.org

 

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually
• Better Prognosis for Some PCI Patients When Operators Perform More Procedures
• Study Finds Significant Variability in Doctors' Angioplasty Death Rates

 

Reference:

Masoudi, F.A., Ponirakis, A., de Lemos, J.A., Jollis, J.G., et al. "Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries," JACC. Published online Dec. 23, 2016. DOI: https://doi.org/10.1016/j.jacc.2016.12.005

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init